I
n a series of letters to the U.S. Army and several senators, Sanofi is denying that it rejected so-called fair pricing for a Zika virus vaccine that the company is developing with American taxpayer funds.
The missives were sent as a growing number of federal and state lawmakers push the U.S. Army to negotiate a more favorable agreement with Sanofi, which is one of the world’s largest vaccine makers and has already received a $43 million U.S. research grant.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
Hmmm – “There may be another reason that Sanofi sent those letters last week.” Yes, could it be their hand was effectively “caught in the cookie jar?” Ah, a little sunlight ‘works wonders!’ (Hopefully, anyway …)